This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down
by Zacks Equity Research
Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.
Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes
by Zacks Equity Research
Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.
BMY or HZNP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. HZNP: Which Stock Is the Better Value Option?
What's in the Cards for Bristol-Myers (BMY) Q1 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BMY) Outperforming Other Medical Stocks This Year?
Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity
by Zacks Equity Research
Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.
Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.
Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study
by Zacks Equity Research
Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $65.60 in the latest trading session, marking a +0.21% move from the prior day.
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe
by Zacks Equity Research
Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.
Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $62.69 in the latest trading session, marking a +0.13% move from the prior day.
Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study
by Zacks Equity Research
Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
by Zacks Equity Research
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.
Novartis (NVS) Teams Up With Artios for Radioligand Therapies
by Zacks Equity Research
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
BMY vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. ILMN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Google, Visa, PayPal, Bristol-Myers Squibb and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Visa, PayPal, Bristol-Myers Squibb and Target
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $63.16 in the latest trading session, marking a +0.22% move from the prior day.
Top Stock Reports for Alphabet, Visa & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and PayPal (PYPL).
3 Reasons Why Bristol Myers (BMY) Is a Great Growth Stock
by Zacks Equity Research
Bristol Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.